CSPC Pharmaceutical Group (HKG:1093) subsidiary, CSPC Megalith Biopharmaceutical, signed an exclusive licensing agreement with Radiance Biopharma for the development and commercialization of the Group's SYS6005 in the US, UK, and several other parts of the world, according to a Wednesday filing with the Hong Kong bourse.
CSPC Megalith will get an initial payment of US$15 million. The pharmaceutical may also receive potential development and regulatory milestone payments of up to US$150 million and potential sales milestone payments of up to US$1.08 billion, with a possibility of tiered royalties based on annual net sales of the Product in the Territory.
This drug uses a special enzyme-based technology to attach a powerful cancer-killing agent (MMAE) to an antibody, targeting cancer cells that have a protein called ROR1.
Other areas in the contract include Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, Australia, and Canada.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。